Benzinga | Jul 15, 2020 08:31AM EDT

Dyadic International Announces Fully Funded Human Health R&D Collaboration With A Pharmaceutical Company

JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a new, fully-funded collaboration with another top five global pharmaceutical company.

"We are very excited to enter into this collaboration with another top five pharmaceutical company to demonstrate the potential of C1 to become a platform of choice for manufacturing certain protein-based biologics. We have been selected for this collaboration because of the attributes of our C1 technology which include, speed of development, high productivity, low cost of goods, among other properties. We expect to express two different types of therapeutic compounds for this collaboration," said Mark Emalfarb, Dyadic's CEO. "Over the past year, we have dedicated our expertise and financial resources to further enhance our core C1 technology and have made significant progress reducing background protease activity and developing a library of differentiated strains, including glycoengineered strains, which we continue to refine. Additionally, we have been able to demonstrate the broad applications of our C1 technology, which in turn has resulted in many new wide-ranging opportunities. Dyadic's pipeline of opportunities with top tier, global animal and human health pharmaceutical companies continues to get larger and more diverse as the C1 technology becomes more widely applicable," concluded Mr. Emalfarb.